A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)

Bischoff, Joachim; Barinoff, Jana; Mundhenke, Christoph; Bauerschlag, Dirk O.; Costa, Serban-Dan; Herr, Daniel; Luebbe, Kristina; Marme, Frederik; Maass, Nicolai; von Minckwitz, Gunter; Grischke, Eva-Maria; Mueller, Volkmar; Schmidt, Marcus; Gerber, Bernd; Kuemmel, Sherko; Schumacher, Claudia; Krabisch, Petra; Seiler, Sabine; Thill, Marc; Nekljudova, Valentina; Loibl, Sibylle

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)

Author:

Bischoff, Joachim; Barinoff, Jana; Mundhenke, Christoph; Bauerschlag, Dirk O.; Costa, Serban-Dan; Herr, Daniel; Luebbe, Kristina; Marme, Frederik; Maass, Nicolai; von Minckwitz, Gunter; Grischke, Eva-Maria; Mueller, Volkmar; Schmidt, Marcus; Gerber, Bernd; Kuemmel, Sherko; Schumacher, Claudia; Krabisch, Petra; Seiler, Sabine; Thill, Marc; Nekljudova, Valentina; Loibl, Sibylle

Tübinger Autor(en):

Grischke, Eva-Maria

Published in:

Anti - Cancer Drugs (2019), Bd. 30, H. 4, S. 394-401

Verlagsangabe:

Lippincott Williams & Wilkins

Language:

English

Full text:

http://dx.doi.org/10.1097/CAD.0000000000000722

ISSN:

1473-5741